Keywords
Pulmonary Medicine ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

543 Search results.

Screening - GSK Milveterol COPD 100527

- 6/18/17 - 1 form, 9 itemgroups, 132 items, 1 language
Itemgroups: Inclusion/Exclusion criteria, Demography, Duration of Asthma, Vital Signs, 12-Lead Electrocardiogram, Pulmonary function, Hematology, Clinical Chemistry, Urinalysis
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Eligibility Prednisone Dependent Asthma NCT02049294

- 6/14/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis; ODM derived from: https://clinicaltrials.gov/show/NCT02049294

Eligibility Pleural Mesothelioma Malignant Advanced NCT02029690

- 6/14/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin; ODM derived from: https://clinicaltrials.gov/show/NCT02029690

Eligibility Pleural Effusion, Malignant NCT02407912

- 6/13/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02407912

Eligibility Non-small Cell Lung Carcinoma NCT02394548

- 6/1/19 - 1 form, 2 itemgroups, 22 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02394548

Eligibility Non-small-cell Lung Carcinoma NCT02400424

- 6/1/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor; ODM derived from: https://clinicaltrials.gov/show/NCT02400424

Eligibility NSCLC Non Small Cells Lung Cancer NCT02293733

- 6/1/19 - 1 form, 1 itemgroup, 12 items, 1 language
Itemgroup: Eligibility Criteria
Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR); ODM derived from: https://clinicaltrials.gov/show/NCT02293733

Eligibility NSCLC NCT02501707

- 6/1/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Echocardiography for RILI Prediction; ODM derived from: https://clinicaltrials.gov/show/NCT02501707

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT02409342

- 6/1/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 110]; ODM derived from: https://clinicaltrials.gov/show/NCT02409342

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT02204345

- 5/31/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology; ODM derived from: https://clinicaltrials.gov/show/NCT02204345

Eligibility Non-Squamous Non-Small Cell Lung Cancer NCT02008227

- 5/31/19 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "OAK"; ODM derived from: https://clinicaltrials.gov/show/NCT02008227

Eligibility Non-Small-Cell Lung Carcinoma NCT02416739

- 5/31/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Anticancer Activity of Nicotinamide on Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02416739